Cardiac Biomarkers Market

The growing burden of cardiovascular diseases (CVDs)is driving the market growth

ly, the burden of cardiovascular diseases (CVDs) is increasing as a result of a number of causes, including smoking, diabetes, obesity, and alterations in lifestyle. The National Centre for Health Statistics estimates that 1 in 4 deaths in the United States occur as a result of coronary artery disease (CAD). The Centers for Disease Control and Prevention estimate that there are roughly 1.5 million myocardial infarction cases reported each year in the US. Additionally, 103,000 people in the UK get myocardial infarction annually, according to Patient Platform Limited.

During the projection period, it is expected that one of the key factors influencing market CAGR will be the rising prevalence of cardiovascular illnesses.

Additionally, the coronavirus disease of 2019 (COVID-19) has been reported in more than 129 countries worldwide, according to the present situation for the year 2020. The impact of COVID-19 on patients with cardiovascular disease is significant, and those who contract the virus are likely to develop heart failure, acute coronary syndrome, and other cardiovascular diseases. Although COVID-19 impacts the respiratory system and other related organs, it has a significant impact on cardiovascular problems, according to an article released by NCBI in March 2020.

Furthermore, 16.4% of 1,527 patients with COVID-19 in various studies from China reported co-morbid disorders. 9.7%, 16.4%, and 17.1% of the patients out of this group, respectively, reported having diabetes, cardiovascular disease, and hypertension. These are a few of the elements that are projected to encourage the use of biomarker testing ly, fueling market expansion.

It is predicted that the market would increase due to vigorous research and development on cardiovascular therapies and the advent of quick and new biomarker testing. For the diagnosis, prognosis, and predictive analysis of cardiovascular illnesses, major market participants are investing in the research and development of new biomarkers. Siemens' high-sensitivity troponin I tests (TnIH) to help with the early identification of myocardial infarctions were approved by the U.S. Food and Drug Administration (FDA) in July 2019.

During the projection period, it is predicted that the development of such innovative tests for the identification of these biomarkers would increase demand for these tests and, as a result, drive the market's growth rate.

The Global Global Cardiac Biomarkers Market Industry is poised for substantial growth, with projections indicating a market value of 19.2 USD Billion in 2024 and a remarkable increase to 68.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 12.21% from 2025 to 2035. Such figures reflect the increasing demand for cardiac biomarkers driven by the rising prevalence of cardiovascular diseases and advancements in diagnostic technologies. The market's expansion is likely to be supported by ongoing research efforts and the development of innovative biomarker solutions.

Regulatory bodies worldwide are increasingly supporting the development and approval of cardiac biomarkers, which is a significant driver for the Global Global Cardiac Biomarkers Market Industry. Streamlined regulatory pathways and guidelines facilitate the introduction of innovative biomarker tests into the market. This supportive environment encourages research and development efforts, enabling companies to bring new products to market more efficiently. As regulatory frameworks evolve to accommodate advancements in biomarker technology, the market is expected to benefit from an influx of novel diagnostic solutions, enhancing overall patient care.

The increasing incidence of cardiovascular diseases globally drives the Global Global Cardiac Biomarkers Market Industry. According to health statistics, cardiovascular diseases remain a leading cause of mortality, accounting for approximately 31% of all deaths worldwide. This alarming trend necessitates the development and adoption of cardiac biomarkers for early diagnosis and management. As healthcare systems prioritize preventive measures, the demand for reliable biomarkers is expected to surge. In 2024, the market is projected to reach 19.2 USD Billion, reflecting the urgent need for innovative diagnostic tools that can enhance patient outcomes and reduce healthcare costs.

Rising awareness regarding heart health among the global population plays a pivotal role in shaping the Global Global Cardiac Biomarkers Market Industry. Educational campaigns and initiatives by health organizations aim to inform individuals about the risks associated with cardiovascular diseases and the importance of early detection. This heightened awareness encourages individuals to seek preventive screenings and diagnostic tests, leading to increased utilization of cardiac biomarkers. Consequently, healthcare providers are likely to expand their offerings of biomarker tests, aligning with the growing demand for proactive health management strategies.

The expansion of healthcare infrastructure globally is a critical driver for the Global Global Cardiac Biomarkers Market Industry. Governments and private sectors are investing heavily in healthcare facilities, particularly in emerging economies, to enhance access to diagnostic services. This investment includes the establishment of specialized cardiac care units and laboratories equipped with advanced diagnostic technologies. Such improvements are expected to facilitate the widespread adoption of cardiac biomarkers, thereby improving patient care. As healthcare systems evolve, the demand for innovative diagnostic solutions is anticipated to grow, further propelling the market forward.

Technological innovations in biomarker discovery and analysis significantly contribute to the growth of the Global Global Cardiac Biomarkers Market Industry. Advances in genomics, proteomics, and metabolomics facilitate the identification of novel cardiac biomarkers, enhancing diagnostic accuracy. For instance, the integration of artificial intelligence and machine learning in data analysis allows for more efficient processing of complex biological data. These advancements not only improve the sensitivity and specificity of tests but also streamline the development of point-of-care testing solutions. As a result, the market is likely to experience substantial growth, with projections indicating a rise to 68.2 USD Billion by 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American cardiac biomarkers market area will dominate this market. This can be ascribed to the advanced healthcare system and the widespread use of cardiac biomarkers as a diagnostic and prognostic tool for diseases. The need for testing products is being driven by the growing elderly population's need for biomarker testing to diagnose diseases such acute myocardial infarction.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CARDIAC BIOMARKERS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe cardiac biomarkers market accounts for the second-largest market share because there are renowned research institutions and market players there. Additionally, the expansion of the industry can be attributed to an increase in the number of partnerships between regional universities and biomarker suppliers, government and industry R&D initiatives involving biomarkers, and the significant initiatives being made to raise awareness of the advantages of biomarkers. Further, the German cardiac biomarkers market held the largest market share, and the UK cardiac biomarkers market was the fastest growing market in the European region

The Asia-Pacific Cardiac biomarkers Market is expected to grow at the fastest CAGR from 2024 to 2032 due to improved affordability for sophisticated cardiac diagnostics, national modernization, and greater disposable income. Government funding for target disease and other research, as well as healthcare costs, have increased due to the rising incidence of cardiovascular diseases (CVDs) in this area. Moreover, China’s cardiac biomarkers market held the largest market share, and the Indian cardiac biomarkers market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the cardiac biomarkers market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, cardiac biomarkers industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  cardiac biomarkers industry to benefit clients and increase the market sector. In recent years, the cardiac biomarkers industry has offered some of the most significant advantages to market. Major players in the cardiac biomarkers market attempting to increase market demand by investing in research and development operations include Novartis AG (Switzerland), Quidel Corporation (US), ACS Biomarker B.V (Netherlands), Randox Laboratories Ltd (UK), Trivitron Healthcare (India), F.

Hoffman La Roche Ltd (Switzerland), Johnson & Johnson Services Inc. (US), Abbott Laboratories (US), Siemens (Germany) and Thermo Fisher Scientific Inc (US).

Siemens AG is a technological firm. Its operations span the disciplines of electrification, automation, and digitalization. The firm creates, develops, and manufactures items, as well as installs complicated systems and projects. It also offers a wide range of customized solutions for specific needs. Siemens is primarily concerned with power generation and distribution, as well as sophisticated infrastructure for buildings and distributed energy systems. In April 2021, the Atellica VTLi patient-side immunoassay analyzer from Siemens Healthineers provides high-sensitivity cardiac troponin I (hs-cTnI) testing findings in eight minutes using a fingerstick blood sample.

Quidel Corp develops, manufactures, and markets quick diagnostic testing systems for the detection and diagnosis of critical diseases and other medical disorders. Immunoassays, molecular assays, virology products such as traditional cell lines, media, specimen collecting equipment, and controls; and speciality goods such as metabolic bone indicators and enzyme linked immunosorbent assays (ELISA) and reagents are among its primary products. Physician offices, hospitals, universities, retail clinics, clinical and reference laboratories, urgent care clinics, pharmacies, and wellness screening facilities are all served by the company's goods.